Diabetes Roadmap: SGLT-2 Inhibitors
Diabetes is a major health problem with the incidence rate continuing to rise in the United States. More than 29 million Americans, or 9.3% of the population, have diabetes, with between 90% and 95% of them having type 2 diabetes. Furthermore, 1.7 million Americans ≥20 years of age were newly diagnosed with diabetes in 2012. There are numerous comorbidities associated with diabetes, including kidney failure, obesity, coronary artery disease, peripheral vascular disease, stroke, and amputations.
The economic burden associated with diabetes is staggering. A recent study found that the cost to treat diagnosed diabetes and undiagnosed diabetes, gestational diabetes, and prediabetes exceeded $322 billion in 2012. With these trends, the cost and debilitating effects of this disease are only going to escalate, unless better glycemic control is achieved.
